WEDNESDAY, July 29, 2009 (HealthDay News) -- The sequencing of the first three multiple myeloma whole genomes has been completed by U.S. scientists, who said this success will lead to a better understanding of this form of blood cancer and advance efforts to develop new therapies.
The analysis of DNA from more than 50 patient samples was conducted as part of the Multiple Myeloma Genomics Initiative. Overall, more than 250 patient samples have been collected and additional multiple myeloma genomes are being sequenced, according to a news release from the Multiple Myeloma Research Foundation (MMRF) and the Multiple Myeloma Research Consortium (MMRC).
The first three complete genomes should be available online to researchers within the next several months, the news release stated.
The data from this research "will play an important role in developing better treatment options for individuals who derive little benefit from existing therapies and may ultimately help provide multiple myeloma patients with the most appropriate treatment for his or her disease. Furthermore, knowledge from this effort could also benefit patients with other types of cancer," Louise Perkins, chief scientific officer at the MMRF and MMRC, said in the news release.
This research initiative "has created an unprecedented opportunity to examine an extraordinary breadth of genomic information to pinpoint the most important genes and cellular processes driving the disease," added Jeffrey Trent, co-principal investigator on the Multiple Myeloma Genomics Initiative. "Such a remarkable dataset exists for very few other cancers; it will no doubt pave the way toward personalized medicine for multiple myeloma patients."
The American Cancer Society has more about multiple myeloma.